Drug Resistance, Fungal

• 

  Subject Areas on Research

  • 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. 
  • A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides. 
  • A colony color method identifies the vulnerability of mitochondria to oxidative damage. 
  • A flucytosine-responsive Mbp1/Swi4-like protein, Mbs1, plays pleiotropic roles in antifungal drug resistance, stress response, and virulence of Cryptococcus neoformans. 
  • A non-canonical RNA degradation pathway suppresses RNAi-dependent epimutations in the human fungal pathogen Mucor circinelloides. 
  • A non-canonical RNAi pathway controls virulence and genome stability in Mucorales. 
  • A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. 
  • A unique fungal two-component system regulates stress responses, drug sensitivity, sexual development, and virulence of Cryptococcus neoformans. 
  • Advancing Functional Genetics Through Agrobacterium-Mediated Insertional Mutagenesis and CRISPR/Cas9 in the Commensal and Pathogenic Yeast Malassezia. 
  • An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. 
  • Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. 
  • Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. 
  • Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. 
  • Antifungal drug resistance evoked via RNAi-dependent epimutations. 
  • Antifungal resistance: the clinical front. 
  • Antifungal treatment in pediatric patients. 
  • Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. 
  • Breakthrough invasive candidiasis in patients on micafungin. 
  • Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. 
  • Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. 
  • Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans. 
  • Candida albicans reprioritizes metal handling during fluconazole stress. 
  • Caspofungin versus amphotericin B for invasive candidiasis. 
  • Cell biology. A fungal Achilles' heel. 
  • Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. 
  • Chitosan Derivatives Active against Multidrug-Resistant Bacteria and Pathogenic Fungi: In Vivo Evaluation as Topical Antimicrobials. 
  • Comparative transcriptome analysis reveals novel roles of the Ras and cyclic AMP signaling pathways in environmental stress response and antifungal drug sensitivity in Cryptococcus neoformans. 
  • Copper Availability Influences the Transcriptomic Response of Candida albicans to Fluconazole Stress. 
  • Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. 
  • Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. 
  • Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 degrees C and in vivo. 
  • Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. 
  • Cryptococcus neoformans phosphoinositide-dependent kinase 1 (PDK1) ortholog is required for stress tolerance and survival in murine phagocytes. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Cytosine deaminase MX cassettes as positive/negative selectable markers in Saccharomyces cerevisiae. 
  • Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. 
  • Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. 
  • Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. 
  • Drug-Resistant Epimutants Exhibit Organ-Specific Stability and Induction during Murine Infections Caused by the Human Fungal Pathogen Mucor circinelloides. 
  • Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. 
  • Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. 
  • Emerging Issues in Antifungal Resistance. 
  • Emerging echinocandins for treatment of invasive fungal infections. 
  • Epigenetic mechanisms of drug resistance in fungi. 
  • Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard. 
  • Evolutionarily Conserved and Divergent Roles of Unfolded Protein Response (UPR) in the Pathogenic Cryptococcus Species Complex. 
  • Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Genes, Pathways, and Mechanisms Involved in the Virulence of Mucorales. 
  • Genomics: Lessons in complexity from yeast. 
  • Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. 
  • Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 
  • Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. 
  • Invasive Candida infections in the neonate. 
  • Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. 
  • Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). 
  • Invasive mycoses: evolving challenges and opportunities in antifungal therapy. Introduction. 
  • Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal. 
  • Management of invasive mycoses in hematology patients: current approaches. 
  • Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and Morphogenesis. 
  • Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii. 
  • Mitochondrial Genome Variation Affects Multiple Respiration and Nonrespiration Phenotypes in Saccharomyces cerevisiae. 
  • Molecular Tools for the Yeast Papiliotrema terrestris LS28 and Identification of Yap1 as a Transcription Factor Involved in Biocontrol Activity. 
  • Natural mismatch repair mutations mediate phenotypic diversity and drug resistance in Cryptococcus deuterogattii. 
  • Network-assisted genetic dissection of pathogenicity and drug resistance in the opportunistic human pathogenic fungus Cryptococcus neoformans. 
  • Nuances of new anti-Aspergillus antifungals. 
  • On Fruits and Fungi: A Risk of Antifungal Usage in Food Storage and Distribution in Driving Drug Resistance in Candida auris 
  • PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. 
  • Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. 
  • Pleiotropy and epistasis within and between signaling pathways defines the genetic architecture of fungal virulence. 
  • Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. 
  • Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. 
  • Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. 
  • Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. 
  • Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. 
  • Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. 
  • Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor. 
  • Role of the Non-Canonical RNAi Pathway in the Antifungal Resistance and Virulence of Mucorales. 
  • Roles for Stress Response and Cell Wall Biosynthesis Pathways in Caspofungin Tolerance in Cryptococcus neoformans. 
  • Sexual reproduction of human fungal pathogens. 
  • Strategies to manage antifungal drug resistance. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. 
  • The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance. 
  • The antifungal pipeline: a reality check. 
  • The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. 
  • Transposon mobilization in the human fungal pathogen Cryptococcus is mutagenic during infection and promotes drug resistance in vitro. 
  • Uncontrolled transposition following RNAi loss causes hypermutation and antifungal drug resistance in clinical isolates of Cryptococcus neoformans. 
  • Unisexual and heterosexual meiotic reproduction generate aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus neoformans. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis. 
  • Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. 
  • Zygomycosis: the re-emerging fungal infection.